These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 32716916)

  • 1. Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
    Kemmerer CL; Pernpeintner V; Ruschil C; Abdelhak A; Scholl M; Ziemann U; Krumbholz M; Hemmer B; Kowarik MC
    PLoS One; 2020; 15(7):e0235449. PubMed ID: 32716916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B cells undergo unique compartmentalized redistribution in multiple sclerosis.
    Haas J; Bekeredjian-Ding I; Milkova M; Balint B; Schwarz A; Korporal M; Jarius S; Fritz B; Lorenz HM; Wildemann B
    J Autoimmun; 2011 Dec; 37(4):289-99. PubMed ID: 21924866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients.
    Kowarik MC; Astling D; Lepennetier G; Ritchie A; Hemmer B; Owens GP; Bennett JL
    Neurotherapeutics; 2021 Jan; 18(1):364-377. PubMed ID: 33258072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients.
    Traub JW; Pellkofer HL; Grondey K; Seeger I; Rowold C; Brück W; Husseini L; Häusser-Kinzel S; Weber MS
    J Neuroinflammation; 2019 Nov; 16(1):228. PubMed ID: 31733652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating memory B cells and plasmablasts are associated with the levels of serum immunoglobulin in patients with ulcerative colitis.
    Wang X; Jiang Y; Zhu Y; Zhang M; Li M; Wang H; Gao P
    J Cell Mol Med; 2016 May; 20(5):804-14. PubMed ID: 26800315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching from injectable to other Disease Modifying Therapies may improve sexual dysfunction in people with Multiple Sclerosis.
    Ala S; Amirkafi A; Kohandel K; Shahmohammadi S; Sahraian MA
    BMC Neurol; 2024 Jul; 24(1):255. PubMed ID: 39048953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of fingolimod on B-cell populations in multiple sclerosis.
    Nakamura M; Matsuoka T; Chihara N; Miyake S; Sato W; Araki M; Okamoto T; Lin Y; Ogawa M; Murata M; Aranami T; Yamamura T
    Mult Scler; 2014 Sep; 20(10):1371-80. PubMed ID: 24526661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effector and regulatory B cells in Multiple Sclerosis.
    Staun-Ram E; Miller A
    Clin Immunol; 2017 Nov; 184():11-25. PubMed ID: 28461106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients.
    Boldrini VO; Marques AM; Quintiliano RPS; Moraes AS; Stella CRAV; Longhini ALF; Santos I; Andrade M; Ferrari B; Damasceno A; Carneiro RPD; Brandão CO; Farias AS; Santos LMB
    Front Immunol; 2022; 13():750660. PubMed ID: 35197967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.
    Fleischer V; Friedrich M; Rezk A; Bühler U; Witsch E; Uphaus T; Bittner S; Groppa S; Tackenberg B; Bar-Or A; Zipp F; Luessi F
    Mult Scler; 2018 Apr; 24(5):632-641. PubMed ID: 28436295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Frequency of Activated Switched Memory B Cells and Its Association With the Presence of Pulmonary Fibrosis in Diffuse Cutaneous Systemic Sclerosis Patients.
    Simon D; Balogh P; Erdő-Bonyár S; Böröcz K; Minier T; Czirják L; Berki T
    Front Immunol; 2021; 12():686483. PubMed ID: 34276673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced non-switched memory B cell subsets cause imbalance in B cell repertoire in systemic sclerosis.
    Simon D; Balogh P; Bognár A; Kellermayer Z; Engelmann P; Németh P; Farkas N; Minier T; Lóránd V; Czirják L; Berki T
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):30-36. PubMed ID: 27056741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
    English C; Aloi JJ
    Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
    Diouf I; Malpas CB; Sharmin S; Roos I; Horakova D; Kubala Havrdova E; Patti F; Shaygannejad V; Ozakbas S; Eichau S; Onofrj M; Lugaresi A; Alroughani R; Prat A; Duquette P; Terzi M; Boz C; Grand'Maison F; Sola P; Ferraro D; Grammond P; Yamout B; Altintas A; Gerlach O; Lechner-Scott J; Bergamaschi R; Karabudak R; Iuliano G; McGuigan C; Cartechini E; Hughes S; Sa MJ; Solaro C; Kappos L; Hodgkinson S; Slee M; Granella F; de Gans K; McCombe PA; Ampapa R; van der Walt A; Butzkueven H; Sánchez-Menoyo JL; Vucic S; Laureys G; Sidhom Y; Gouider R; Castillo-Trivino T; Gray O; Aguera-Morales E; Al-Asmi A; Shaw C; Al-Harbi TM; Csepany T; Sempere AP; Treviño Frenk I; Stuart EA; Kalincik T
    J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):1004-1011. PubMed ID: 37414534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of dimethyl fumarate as first line therapy in MS patients - one center real life observation study.
    Sałacińska D; Pogoda A; Żółkiewicz J; Stępień A
    Pol Merkur Lekarski; 2019 Dec; 47(282):221-225. PubMed ID: 31945023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Derailed B cell homeostasis in patients with mixed connective tissue disease.
    Hajas A; Barath S; Szodoray P; Nakken B; Gogolak P; Szekanecz Z; Zold E; Zeher M; Szegedi G; Bodolay E
    Hum Immunol; 2013 Jul; 74(7):833-41. PubMed ID: 23608739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
    Hawke S; Zinger A; Juillard PG; Holdaway K; Byrne SN; Grau GE
    J Neuroimmunol; 2020 Dec; 349():577392. PubMed ID: 33007647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [THE IDENTIFICATION OF SUB-POPULATIONS OF B-LYMPHOCYTES OF PERIPHERAL BLOOD USING TECHNIQUE OF FLOW CYTOFLUOROMETRY IN HEALTHY INDIVIDUALS AND PATIENTS WITH RHEUMATOID DISEASES].
    Suponitskaia EV; Aleksankin AP; Aleksandrova EN; Avdeeva AS; Panafidina TA; Verijnikova JG; Nasonov EL
    Klin Lab Diagn; 2015 Jun; 60(6):30-3. PubMed ID: 26466448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
    Blumenfeld S; Staun-Ram E; Miller A
    J Autoimmun; 2016 Jun; 70():40-51. PubMed ID: 27055778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.